Creator Post Archive
Martin Shkreli
Browse the full post archive, then jump into the source post to inspect linked mentions and linked signals.
Oct 28, 2026
Moderna Needs More Than a $10 Billion Cancer Drug
Martin Shkreli analyzes the valuation and pipeline prospects of Moderna and Zura Bio. He expresses skepticism about Moderna's current valuation relative to its revenue potential, while showing interest in Zura Bio's clinical pipeline despite potential dilution risks.
Oct 27, 2026
Humacyte & Netlist: Great Stocks or Great Stories?
Martin Shkreli critiques a guest's speculative biotech and tech portfolio, advising her to exit positions in Humacyte and Butterfly Network while suggesting a more disciplined, business-focused approach to investing. He expresses skepticism toward companies with low revenue or questionable business models, labeling several of the guest's picks as 'stinkers' or 'scams'.
Oct 26, 2026
How I Read the Stock Market in Real Time
Martin Shkreli demonstrates his real-time market monitoring tools, including historical return histograms and time-and-sales data, while observing intraday market movements and upcoming earnings catalysts. He discusses the difficulty of predicting semiconductor cycles for Nvidia and emphasizes the importance of tracking institutional flow.
Oct 14, 2026
My Gen-Z Intern Thinks Showing Up To Work Is Optional
Martin Shkreli discusses workplace dynamics with his intern, Keith, while touching on various stock positions and market sentiment. The conversation includes a critique of current market performance for specific biotech holdings and a reflection on the challenges of managing young talent in a volatile market.
Oct 14, 2026
Dario Amodei Is Wrong About AI
Martin Shkreli discusses the AI landscape, dismissing fear-mongering around AI safety while expressing a bullish outlook on the sector. He highlights Meta as a top pick due to its distribution and product execution, while remaining long on semiconductors despite potential long-term technological shifts.
Aug 14, 2026
8/14/26 +6% since 7/1
The creator discusses shorting Capital (CAPR) and Palantir (PLTR), expressing skepticism about their future performance and current valuations. He also mentions taking over a trade from a colleague, which resulted in a loss, and briefly touches on other market movements like AMD, NVDA, and Tesla.
Aug 13, 2026
8/13/26 +5% since 7/1
The creator discusses several stocks, highlighting Omeros's strong revenue announcement and potential for growth. They also comment on the performance of other companies like Cerebrus, Tapestry, Cisco, and Open Door, noting both positive and negative movements and offering brief opinions on some.
Aug 11, 2026
8/11/26 +17% since 7/1
Martin Shkreli discusses various stocks, including Rocket Lab, Intel, Micron, Sandisk, Nvidia, Apple, and Trading Heavy. He expresses a short interest in Rocket Lab and notes Sandisk's profitability. The creator also touches on market maker programs, trading strategies, and critiques Michael Barry.
Jul 1, 2026
7/1/26 -2.1%
Martin Shkreli discusses Meta's potential move into cloud services, initially expressing concern that it could reduce demand for component makers like Nvidia. However, he later revises his view, suggesting that if Meta is offering compute power alongside their models, it could be bullish. He also briefly mentions Neuralink and Amazon.
Jun 30, 2026
6/30/26 +0.93%
The creator discusses various topics including technology, the human spirit, and personal hustle. He mentions Nvidia as a hardware company and highlights Asana Sciences as a generational opportunity. A significant portion of the content is dedicated to a critique of the FDA's stance on BPC 157, a peptide, arguing against its approval due to lack of evidence and questionable research origins.
Jun 29, 2026
6/29/26 +0.25%
Martin Shkreli discusses Nvidia's position as a hardware company, a potential generational opportunity in a small biotech, and the upcoming adcom for Capricorn. He also touches on Micron's stock movement due to memory news, Intel's entry into the memory market, Comcast spinning off NBC Universal, and Rocket Lab's acquisition of Idium, expressing a desire to short Rocket Lab based on the acquisition headline.
Jun 26, 2026
6/26/26 -0.80%
The creator discusses several stocks, including Micron, expressing a bullish sentiment on its memory cycle and revenue growth, noting its significant investment in property, plant, and equipment. He also touches on other companies like Aadia, Emix Bioarm, and Capricorn, with mixed or unresolved sentiments.
May 4, 2026
5/4/26 - we're back until 11am
Martin Shkreli discusses the nature of companies like Nvidia, contrasting hardware and software, and expresses strong interest in Casada Sciences, a small biotech company he views as a generational opportunity. He also comments on the significant drop in Xanadoo's stock price following a lock-up expiry, attributing it to early shareholders selling their shares.
Apr 6, 2026
4/6/26 - sorry for the wait!
Martin Shkreli returns after an illness, discussing various topics including biotech deals, drug development, and personal health regimens. He touches on Seleno acquisition by Nurocran, Lightwave Logic, Amgen's execution, and mentions Biogen and Viatris with some commentary.
Mar 20, 2026
3/20/26 - sorry for the wait!
The creator discusses several companies including Super Micro, Planet Labs, Moderna, Denali, and Arrowhead. He expresses surprise at Super Micro's stock drop, notes Planet Labs' record revenue, and highlights Arrowhead as a significant past winner and Surreptit's partner.
Feb 25, 2026
2/25/26 - NVDA earnings release
Dry-run Step 5 insert for NVDA
Dec 5, 2025
12/4/25 challenge account -100% RIP - QCLS is the new thing
Martin Shkreli discusses the failure of his challenge account, attributing it to a bad pick in Capra. He expresses renewed interest in QCLS, a company focused on photonic computing, which he believes is superior to quantum computing. Shkreli plans to take a job at QCLS and will shift his focus from trading to analyzing stocks for his community.
Dec 3, 2025
12/3/25 CAPR WATCH
The creator is highly skeptical of Capricorn Therapeutics' (CAPR) reported topline data for the hope three trial, alleging the company has changed its primary endpoint and is misrepresenting the results. He believes the reported changes are statistically insignificant and indicative of past "shenanigans" that led to approval failures.
Dec 2, 2025
12/2/25 +479% CAPR WATCH
The creator discusses several stocks including Corvus Pharmaceuticals (CAPR), Nvidia (NVDA), Apple (AAPL), Genex (GENX), and AstraZeneca (AZN). The primary focus is on CAPR, which is awaiting significant binary event data. The creator also touches on market movements and trading commissions.
Nov 20, 2025
11/19/25 +474% part 2 - NVDA WATCH
The creator is closely watching Nvidia's upcoming earnings report, anticipating a potential "shock and awe" performance with strong revenue and guidance. While not currently holding a position, the creator expresses a long bias if forced to choose.
Nov 10, 2025
11/10/25 +536% CAPR after close!
The creator discusses several stocks including Palantir and Nvidia, noting past successful trades with call options. He expresses a short position on Capricor (CAPR), citing it as a high conviction trade despite acknowledging the company's earnings call. He also mentions being down on IHRX and generally advises against options trading for inexperienced individuals.
Sep 12, 2025
9/12/25 +59% atyr watch day 8
The creator discusses a bubble-like market environment and mentions several stocks including Yegg, Visor, and IonQ. He notes having previously shorted Visor at its peak and expresses a painful experience shorting another "cult stock". The video also touches on IonQ's investor day and its quantum leadership.
Sep 11, 2025
9/11/25 +58% atyr watch day 7
The creator discusses the stock Atyr (ATYR), noting the new CEO's importance and the potential for a turnaround. They are working on a research report for ATYR, delving into its 2014 research papers and the scientific basis for its treatments, while also mentioning UCO as a potentially interesting but uncertain business.
Sep 8, 2025
9/8/25 +56% atyr watch day 4
The creator expresses a negative view on the biotech sector, calling it a "dead sector" and a "waste of time," and suggests that investors would be better off following software instead.
Sep 8, 2025
9/8/25 +55% atyr watch day 4 PART 2
The creator discusses the biotech company Avivax, noting its current call and potential. He also reflects on Celgene's history, particularly its hit product Revlimid and its limitations. The creator mentions a potential trade on 'Octo' due to its perceived market inefficiency, drawing a parallel to a past successful trade with Espa.
Showing 1-25 of 39 posts · Page 1 of 2